Euglycemic diabetic ketoacidosis associated with a sodium-glucose co transporter 2 inhibitor use in a trauma patient : A case report
Abstract
Abstract Background Sodium-glucose co-transporter 2 inhibitors (SGLT2i), like empagliflozin, are widely prescribed for managing type 2 diabetes mellitus. However, they carry a rare but serious risk: euglycemic diabetic ketoacidosis (EDKA). EDKA's atypical presentation, characterized by metabolic acidosis and ketosis despite normal blood glucose levels, often delays diagnosis, posing significant challenges in intensive care. Case Presentation: We report the case of a 74-year-old female with type 2 diabetes on empagliflozin, gliclazide, and metformin. Admitted after severe trauma from a road traffic accident, she subsequently developed EDKA. This was fostered by septic shock due to methicillin-susceptible Staphylococcus aureus cellulitis. All home medications were discontinued. EDKA was successfully managed with fluid volume expansion, continuous intravenous insulin and dextrose infusions, resolving her metabolic derangements within five days. Conclusion SGLT2i use is associated with a significantly increased risk of EDKA. Early diagnosis is critical due to its potential lethal consequences. Reintroducing SGLT2i in ICU patients, especially trauma patients at high sepsis risk, requires careful, daily reassessment given their unpredictable clinical course.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.